Analyst Rating Update on Heron Therapeutics (HRTX)

Heron Therapeutics (HRTX) : 8 brokerage houses believe that Heron Therapeutics (HRTX) is a Strong Buy at current levels. Zacks Investment Research suggests a Sell with a rank of 4.The median of all the 8 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.

Heron Therapeutics (HRTX) : The consensus price target for Heron Therapeutics (HRTX) is $46 for the short term with a standard deviation of $5.32. The most optimist securities analyst among the 8 who monitor the stock believes that the stock can reach $55, however, the pessimist price target for the company is $38.

For the current week, the company shares have a recommendation consensus of Buy.


Heron Therapeutics (NASDAQ:HRTX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $17.92 and $17.75 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $19.76. The buying momentum continued till the end and the stock did not give up its gains. It closed at $19.43, notching a gain of 6.76% for the day. The total traded volume was 859,970 . The stock had closed at $18.20 on the previous day.

Heron Therapeutics, Inc. is a biotechnology company. The Company uses its technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals. The Companys product candidate, SUSTOL (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). Sustol is in Phase III Clinical trials. The Companys product development program also focuses on identifying new delivery methods and formulations utilizing known compounds that may expand or extend the therapeutic effort, or eliminate the drawbacks of current therapies. The Companys other product candidates include HTX-019 for CINV, which is in Preclinical state; HTX-011 for Post-operative pain management, which is in Phase I trials, and HTX-003 for chronic pain management, which is in Preclinical state.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *